Last €53.50 EUR
Change Today +0.368 / 0.69%
Volume 675.0
4AB On Other Exchanges
New York
EN Paris
As of 9:32 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (4AB) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/22/14 - €59.27
52 Week Low
04/14/14 - €32.57
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ABBVIE INC (4AB)

abbvie inc (4AB) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.

26,000 Employees
Last Reported Date: 02/20/15
Founded in 2012

abbvie inc (4AB) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $790.0K
Executive Vice President of Commercial Operat...
Total Annual Compensation: $710.0K
Executive Vice President of Business Developm...
Total Annual Compensation: $900.0K
Senior Vice President of Human Resources
Total Annual Compensation: $545.0K
Compensation as of Fiscal Year 2013.

abbvie inc (4AB) Key Developments

AbbVie Inc. Announces Results from Phase 2 Portion of its Phase2/3 Open-Label Study, TURQUOISE-I

AbbVie Inc. announced that results from part one of the Phase 2 portion of its Phase2/3 open-label study, TURQUOISE-I, in genotype 1 chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection were published online in The Journal of the American Medical Association (JAMA). Additional sub-analyses also will be presented in both oral and poster presentations on Feb. 26, at the Annual Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, Wash. The TURQUOISE-I study showed patients co-infected with genotype 1 (GT1) hepatitis C virus (HCV) and HIV-1 receiving VIEKIRA PAK ¢ and ribavirin (RBV) for 12 weeks or 24 weeks achieved sustained virologic response rates 12 weeks post-treatment (SVR12) of 94% (n=29/31) and 91% (n=29/32), respectively. The SVR12 rates were 91% (n=51/56) for subjects with HCV GT1a infection and 100% (n=7/7) for those with HCV GT1b infection. VIEKIRA PAK is contraindicated with efavirenz (Sustiva) because co-administration is poorly tolerated and results in liver enzyme elevations. The ritonavir component of VIEKIRA PAK is an HIV-1 protease inhibitor and can select for HIV-1 protease inhibitor resistance. To reduce this risk, HCV/HIV-1 co-infected patients should also be on a suppressive antiretroviral (ART) drug regimen. The most common adverse events occurring in at least 10% of patients in TURQUOISE-I were fatigue (48%), insomnia (19%), nausea (17%), headache (16%), itching (13%), cough (11%), irritability (10%), and yellowing of the eyes (10%). TURQUOISE-I is an ongoing Phase 2/3, multi-center, randomized, open-label study evaluating the efficacy and safety of VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir (25/150/100 mg once daily) and dasabuvir (250 mg twice daily) with RBV (weight based dosing of 1000 mg or 1200 mg per day divided twice daily) for 12 or 24 weeks in adult patients with chronic GT1 HCV infection with or without compensated liver cirrhosis who are also infected with HIV-1. Study patients were either new to therapy (treatment-naïve) or had failed previous treatment with pegylated interferon and RBV (treatment-experienced), had a stable immune status (CD4+ counts of â ¥200 cells/mm3 or CD4+ % â ¥14%). Patients were on a stable HIV-1 ART regimen that included tenofovir disoproxil fumarate plus emtricitabine or lamivudine, administered with ritonavir-boosted atazanavir or raltegravir. Patients on atazanavir stopped the ritonavir component of their HIV-1 ART regimen upon initiating treatment with VIEKIRA PAK + RBV. Atazanavir was taken with the morning dose of VIEKIRA PAK. The ritonavir component of the HIV-1 ART regimen was restarted after completion of treatment with VIEKIRA PAK and RBV. Of the five patients who were non-responders, one experienced virologic failure, one discontinued treatment, one experienced relapse and two patients had evidence of HCV reinfection post-treatment. Based on the results of this study, prescribers should follow the same dosing recommendations for mono-infected patients as outlined in the VIEKIRA PAK prescribing information. VIEKIRA PAK ¢ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) has been studied in a broad range of genotype 1 (GT1) patients with chronic hepatitis C virus (HCV) infection, ranging from treatment-na¯ve to some of the most difficult to treat, such as patients with compensated (mild, Child-Pugh A) cirrhosis of the liver, HCV/HIV-1 co-infection, liver transplant recipients with normal hepatic function and mild fibrosis, and those who have failed previous treatment with pegylated interferon (pegIFN) and ribavirin (RBV). VIEKIRA PAK is not recommended in patients with moderate hepatic impairment (Child-Pugh B), and is contraindicated in patients with severe hepatic impairment (Child-Pugh C). VIEKIRA PAK consists of the fixed-dose combination of ombitasvir 25mg (an NS5A inhibitor), paritaprevir 150mg (an NS3/4A protease inhibitor), and ritonavir 100mg (an inhibitor of an enzyme that breaks down paritaprevir), dosed once daily with a meal, and dasabuvir 250mg (a non-nucleoside NS5B palm polymerase inhibitor), dosed twice daily with a meal. VIEKIRA PAK is taken for 12 weeks, except in GT1a patients with cirrhosis, who should take it for 24 weeks. Ribavirin should be co-administered in GT1a patients, and in all patients who have cirrhosis or who have received a liver transplant.

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on May 15, 2015

The board of directors of AbbVie Inc. increased the company's quarterly cash dividend by 4% from $0.49 per share to $0.51 per share. The cash dividend is payable on May 15, 2015 to stockholders of record at the close of business on April 15, 2015.

AbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C

AbbVie submitted a new drug application to the Japanese Ministry of Health, Labour and Welfare seeking approval for the company's investigational, all-oral, ribavirin and interferon -free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir, dosed once daily. The submission is for the treatment of patients with genotype 1 chronic hepatitis C virus infection. The NDA is supported by the Phase 3 GIFT-I study, which met its primary endpoint, achieving a 95% sustained virologic response rate at 12 weeks post-treatment in the sub-group of previously untreated, non-cirrhotic, adult genotype 1b (GT1b)-infected Japanese patients who were eligible for therapy with IFN and had a high viral load. Additionally, two patients without cirrhosis discontinued treatment due to adverse events. GIFT-I included a placebo-controlled arm and studied patients with and without compensated cirrhosis, who were new to therapy or treatment-experienced. AbbVie studied a two direct-acting antiviral regimen without RBV in Japan due to patient and viral characteristics specific to the Japanese population, including high prevalence of GT1b. In Japan, approximately 1.5 to 2 million people are living with HCV.1 Genotype 1 is the most common HCV genotype in Japan with 60% to 70% of patients infected and, of those, about 95% are infected with the GT1b sub-type.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4AB:GR €53.50 EUR +0.368

4AB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.00 USD -0.089
Amgen Inc $157.17 USD -1.39
Bristol-Myers Squibb Co $61.32 USD -0.60
Eli Lilly & Co $69.97 USD -0.40
Novo Nordisk A/S kr314.10 DKK -0.90
View Industry Companies

Industry Analysis


Industry Average

Valuation 4AB Industry Range
Price/Earnings 55.2x
Price/Sales 4.8x
Price/Book 55.2x
Price/Cash Flow 54.3x
TEV/Sales 3.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at